Shreveport Urologist, Dr. Brian Mazzarella of Regional Urology, Named UroLift® Center of Excellence

Share Article

Designation Recognizes Commitment to Exemplary Care, Deep UroLift Experience

News Image
The UroLift System is a minimally invasive treatment option that typically allows patients to discontinue taking medications and doesn’t interfere with sexual function.

Regional Urology of Shreveport, LA today announced that Dr. Brian Mazzarella, M.D. has been named a UroLift® Center of Excellence. He is the first physician in the state of Louisiana to achieve such an honor. This recognition is based on his commitment to exemplary care for men suffering from urinary tract symptoms and his high level of training and experience with the UroLift System in treating men with Benign Prostatic Hyperplasia or BPH.

“The introduction of the UroLift System as a treatment option for men with enlarged prostate has fundamentally changed how I treat this condition. Patients finally have a safe and simple alternative to procedures that involve cutting, heating, or removal of prostate tissue,” said Dr. Mazzarella. “The UroLift System is a minimally invasive treatment option that typically allows patients to discontinue taking medications and doesn’t interfere with sexual function. I am honored to be leading the state of Louisiana by offering this breakthrough procedure that betters the lives of many.”

The UroLift System is a proven treatment that can get men off BPH medications and allows them to avoid major surgery, while preserving sexual function. Long-term clinical data from the LIFT randomized study published in Urologic Clinics of North America showed that, after four years, patients treated with the UroLift device continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift device compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

More than 37 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.
 
To schedule a consultation with Dr. Mazzarella, please call 318-683-0411.

About the UroLift System

NeoTract Inc.’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at http://www.UroLift.com.
 
                                                                                         #  #  #
 
Media Contact:
Amy Cramer
M: 650-391-3714
amy(at)healthandcommerce.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Serpa
Health+Commerce
+1 4156761923
Email >